Mills GB - Search Results

1

Integrative Analysis Identifies Four Molecular and Clinical Subsets in Uveal Melanoma.

Robertson AG, Shih J, Yau C, Gibb EA, Oba J, Mungall KL, Hess JM, Uzunangelov V, Walter V, Danilova L, Lichtenberg TM, Kucherlapati M, Kimes PK, Tang M, Penson A, Babur O, Akbani R, Bristow CA, Hoadley KA, Iype L, Chang MT; TCGA Research Network; Cherniack AD, Benz C, Mills GB, Verhaak RGW, Griewank KG, Felau I, Zenklusen JC, Gershenwald JE, Schoenfield L, Lazar AJ, Abdel-Rahman MH, Roman-Roman S, Stern MH, Cebulla CM, Williams MD, Jager MJ, Coupland SE, Esmaeli B, Kandoth C, Woodman SE. Robertson AG, et al. Among authors: mills gb. Cancer Cell. 2017 Aug 14;32(2):204-220.e15. doi: 10.1016/j.ccell.2017.07.003. Cancer Cell. 2017. PMID: 28810145 Free PMC article.

2

Human hematopoietic cell express two forms of the cytokine receptor common gamma-chain (gamma c).

Shi YF, Hill M, Novak A, Chen ZQ, Wang RX, Liew CC, Mills GB. Shi YF, et al. Among authors: mills gb. Cell Res. 1997 Dec;7(2):195-205. doi: 10.1038/cr.1997.20. Cell Res. 1997. PMID: 9444398

3

Involvement of JNK-mediated pathway in EGF-mediated protection against paclitaxel-induced apoptosis in SiHa human cervical cancer cells.

Liu B, Fang M, Lu Y, Lu Y, Mills GB, Fan Z. Liu B, et al. Among authors: mills gb. Br J Cancer. 2001 Jul 20;85(2):303-11. doi: 10.1054/bjoc.2001.1910. Br J Cancer. 2001. PMID: 11461094 Free PMC article.

4

Linking molecular therapeutics to molecular diagnostics: inhibition of the FRAP/RAFT/TOR component of the PI3K pathway preferentially blocks PTEN mutant cells in vitro and in vivo.

Mills GB, Lu Y, Kohn EC. Mills GB, et al. Proc Natl Acad Sci U S A. 2001 Aug 28;98(18):10031-3. doi: 10.1073/pnas.191379498. Proc Natl Acad Sci U S A. 2001. PMID: 11526226 Free PMC article. No abstract available.

5

Inhibition of phosphatidylinositol 3'-kinase increases efficacy of paclitaxel in in vitro and in vivo ovarian cancer models.

Hu L, Hofmann J, Lu Y, Mills GB, Jaffe RB. Hu L, et al. Among authors: mills gb. Cancer Res. 2002 Feb 15;62(4):1087-92. Cancer Res. 2002. PMID: 11861387

6

Targeting PI3K-AKT pathway for cancer therapy.

Lu Y, Wang H, Mills GB. Lu Y, et al. Among authors: mills gb. Rev Clin Exp Hematol. 2003 Jun;7(2):205-28. Rev Clin Exp Hematol. 2003. PMID: 14763163 Review.

7

Molecular therapeutics: promise and challenges.

Kohn EC, Lu Y, Wang H, Yu Q, Yu S, Hall H, Smith DL, Meric-Bernstam F, Hortobagyi GN, Mills GB. Kohn EC, et al. Among authors: mills gb. Semin Oncol. 2004 Feb;31(1 Suppl 3):39-53. doi: 10.1053/j.seminoncol.2004.01.009. Semin Oncol. 2004. PMID: 15052542 Review.

8

Exploiting the PI3K/AKT pathway for cancer drug discovery.

Hennessy BT, Smith DL, Ram PT, Lu Y, Mills GB. Hennessy BT, et al. Among authors: mills gb. Nat Rev Drug Discov. 2005 Dec;4(12):988-1004. doi: 10.1038/nrd1902. Nat Rev Drug Discov. 2005. PMID: 16341064 Review.

9

BRIT1 regulates early DNA damage response, chromosomal integrity, and cancer.

Rai R, Dai H, Multani AS, Li K, Chin K, Gray J, Lahad JP, Liang J, Mills GB, Meric-Bernstam F, Lin SY. Rai R, et al. Among authors: mills gb. Cancer Cell. 2006 Aug;10(2):145-57. doi: 10.1016/j.ccr.2006.07.002. Epub 2006 Jul 27. Cancer Cell. 2006. PMID: 16872911 Free PMC article.

10

Reverse phase protein array: validation of a novel proteomic technology and utility for analysis of primary leukemia specimens and hematopoietic stem cells.

Tibes R, Qiu Y, Lu Y, Hennessy B, Andreeff M, Mills GB, Kornblau SM. Tibes R, et al. Among authors: mills gb. Mol Cancer Ther. 2006 Oct;5(10):2512-21. doi: 10.1158/1535-7163.MCT-06-0334. Mol Cancer Ther. 2006. PMID: 17041095

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

1,134 results

Search Page